Livforsakringsbolaget Skandia Omsesidigt Purchases 537 Shares of Eli Lilly and Company (NYSE:LLY)

Livforsakringsbolaget Skandia Omsesidigt lifted its position in shares of Eli Lilly and Company (NYSE:LLY) by 3.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 15,302 shares of the company’s stock after purchasing an additional 537 shares during the period. Eli Lilly and Company comprises 0.9% of Livforsakringsbolaget Skandia Omsesidigt’s investment portfolio, making the stock its 24th largest holding. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Eli Lilly and Company were worth $8,920,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. grew its holdings in shares of Eli Lilly and Company by 0.9% during the third quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock worth $37,908,273,000 after purchasing an additional 659,838 shares during the last quarter. Morgan Stanley lifted its stake in shares of Eli Lilly and Company by 0.7% in the third quarter. Morgan Stanley now owns 12,545,572 shares of the company’s stock worth $6,738,605,000 after acquiring an additional 83,915 shares during the period. Northern Trust Corp lifted its stake in shares of Eli Lilly and Company by 3.6% in the third quarter. Northern Trust Corp now owns 10,158,275 shares of the company’s stock worth $5,456,314,000 after acquiring an additional 355,317 shares during the period. Norges Bank acquired a new position in shares of Eli Lilly and Company in the fourth quarter worth approximately $3,416,206,000. Finally, International Assets Investment Management LLC lifted its stake in shares of Eli Lilly and Company by 61,268.8% in the fourth quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock worth $42,802,530,000 after acquiring an additional 7,330,815 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

LLY has been the topic of a number of recent analyst reports. Truist Financial reaffirmed a “buy” rating and issued a $850.00 price objective on shares of Eli Lilly and Company in a research note on Friday, March 22nd. Bank of America lifted their price objective on Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research note on Friday, March 1st. The Goldman Sachs Group lifted their price objective on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research note on Thursday, April 11th. TheStreet raised Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $815.00 price target on shares of Eli Lilly and Company in a research note on Monday. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $728.05.

Eli Lilly and Company Stock Performance

NYSE:LLY traded up $4.13 during trading on Wednesday, reaching $750.87. The company’s stock had a trading volume of 3,068,748 shares, compared to its average volume of 3,085,965. The firm has a market cap of $713.45 billion, a price-to-earnings ratio of 128.75, a price-to-earnings-growth ratio of 1.64 and a beta of 0.34. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. The firm has a 50 day moving average of $763.51 and a 200-day moving average of $657.01. Eli Lilly and Company has a 12 month low of $367.35 and a 12 month high of $800.78.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. The firm had revenue of $9.35 billion during the quarter, compared to the consensus estimate of $8.95 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The business’s revenue for the quarter was up 28.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.09 EPS. Research analysts expect that Eli Lilly and Company will post 12.52 EPS for the current fiscal year.

Insider Activity

In other news, major shareholder Lilly Endowment Inc sold 54,032 shares of the company’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $645.07, for a total transaction of $34,854,422.24. Following the transaction, the insider now owns 99,488,598 shares of the company’s stock, valued at approximately $64,177,109,911.86. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.